Saturday, September 30, 2023
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

Can the AI driving ChatGPT help to detect early signs of Alzheimer’s disease?

in Health
Can the ai driving chatgpt help to detect early signs of alzheimer’s disease?
Share on LinkedinShare on WhatsApp

The artificial intelligence algorithms behind the chatbot program ChatGPT — which has drawn attention for its ability to generate humanlike written responses to some of the most creative queries — might one day be able to help doctors detect Alzheimer’s Disease in its early stages. Research from Drexel University’s School of Biomedical Engineering, Science and Health Systems recently demonstrated that OpenAI’s GPT-3 program can identify clues from spontaneous speech that are 80% accurate in predicting the early stages of dementia.

Finding an Early Sign

The current practice for diagnosing Alzheimer’s Disease typically involves a medical history review and lengthy set of physical and neurological evaluations and tests. While there is still no cure for the disease, spotting it early can give patients more options for therapeutics and support. Because language impairment is a symptom in 60-80% of dementia patients, researchers have been focusing on programs that can pick up on subtle clues — such as hesitation, making grammar and pronunciation mistakes and forgetting the meaning of words — as a quick test that could indicate whether or not a patient should undergo a full examination.

“We know from ongoing research that the cognitive effects of Alzheimer’s Disease can manifest themselves in language production,” said Hualou Liang, PhD, a professor in Drexel’s School of Biomedical Engineering, Science and Health Systems and a coauthor of the research. “The most commonly used tests for early detection of Alzheimer’s look at acoustic features, such as pausing, articulation and vocal quality, in addition to tests of cognition. But we believe the improvement of natural language processing programs provide another path to support early identification of Alzheimer’s.”

A Program that Listens and Learns

GPT-3, officially the third generation of OpenAI’s General Pretrained Transformer (GPT), uses a deep learning algorithm — trained by processing vast swaths of information from the internet, with a particular focus on how words are used, and how language is constructed. This training allows it to produce a human-like response to any task that involves language, from responses to simple questions, to writing poems or essays.

GPT-3 is particularly good at “zero-data learning” — meaning it can respond to questions that would normally require external knowledge that has not been provided. For example, asking the program to write “Cliff’s Notes” of a text, would normally require an explanation that this means a summary. But GPT-3 has gone through enough training to understand the reference and adapt itself to produce the expected response.

“GPT3’s systemic approach to language analysis and production makes it a promising candidate for identifying the subtle speech characteristics that may predict the onset of dementia,” said Felix Agbavor, a doctoral researcher in the School and the lead author of the paper. “Training GPT-3 with a massive dataset of interviews — some of which are with Alzheimer’s patients — would provide it with the information it needs to extract speech patterns that could then be applied to identify markers in future patients.”

Seeking Speech Signals

The researchers tested their theory by training the program with a set of transcripts from a portion of a dataset of speech recordings compiled with the support of the National Institutes of Health specifically for the purpose of testing natural language processing programs’ ability to predict dementia. The program captured meaningful characteristics of the word-use, sentence structure and meaning from the text to produce what researchers call an “embedding” — a characteristic profile of Alzheimer’s speech.

They then used the embedding to re-train the program — turning it into an Alzheimer’s screening machine. To test it they asked the program to review dozens of transcripts from the dataset and decide whether or not each one was produced by someone who was developing Alzheimer’s.

Running two of the top natural language processing programs through the same paces, the group found that GPT-3 performed better than both, in terms of accurately identifying Alzheimer’s examples, identifying non-Alzheimer’s examples and with fewer missed cases than both programs.

A second test used GPT-3’s textual analysis to predict the score of various patients from the dataset on a common test for predicting the severity of dementia, called the Mini-Mental State Exam (MMSE).

The team then compared GPT-3’s prediction accuracy to that of an analysis using only the acoustic features of the recordings, such as pauses, voice strength and slurring, to predict the MMSE score. GPT-3 proved to be almost 20% more accurate in predicting patients’ MMSE scores.

“Our results demonstrate that the text embedding, generated by GPT-3, can be reliably used to not only detect individuals with Alzheimer’s Disease from healthy controls, but also infer the subject’s cognitive testing score, both solely based on speech data,” they wrote. “We further show that text embedding outperforms the conventional acoustic feature-based approach and even performs competitively with fine-tuned models. These results, all together, suggest that GPT-3 based text embedding is a promising approach for AD assessment and has the potential to improve early diagnosis of dementia.”

Continuing the Search

To build on these promising results, the researchers are planning to develop a web application that could be used at home or in a doctor’s office as a pre-screening tool.

“Our proof-of-concept shows that this could be a simple, accessible and adequately sensitive tool for community-based testing,” Liang said. “This could be very useful for early screening and risk assessment before a clinical diagnosis.”

Courtesy Science Daily. By Drexel University. Article available here.

Tags: AIAlzheimmersDiagnostics

Related Posts

Wildfire smoke has cleared, but health threat lingers
Environment

Wildfire smoke has cleared, but health threat lingers

Alzheimer’s drug a step closer to fda approval
Food

Alzheimer’s drug a step closer to FDA approval

How wildfire smoke affects human health
Environment

How wildfire smoke affects human health

- mpox no longer a global health emergency, who says
Food

Mpox no longer a global health emergency, WHO says

5 questions facing the pharma industry in 2023
Food

Baxter to divest biopharma solutions unit for $4.25 billion

Covid-19 no longer a health emergency, who says
Business

COVID-19 no longer a health emergency, WHO says

Us health regulators weigh first over-the-counter birth control pill
Food

US health regulators weigh first over-the-counter birth control pill

How your skin and body benefit from sunshine
Food

How your skin and body benefit from sunshine

- costa rican coffee exports fall by 20% in april
Food

Costa Rican coffee exports fall by 20% in April

- bird flu surge sees scientists seeking clues to prevent next pandemic
Health

Bird flu surge sees scientists seeking clues to prevent next pandemic

No Result
View All Result

Recent Posts

  • Delta to modify changes to frequent flyer program
  • Mineral mining could affect US water supply
  • Netflix nixes DVD rental subscriptions
  • Costco begins selling gold bars to customers
  • Pending home sales sink to new low

Recent Comments

  • Juul Unveils Cutting-Edge Vaping Tech: Navigating FDA Uncertainties – iStreetPark Blog on Juul hopes FDA won’t ban its new high-tech vape
  • CEO North America, August - September 2023 - CEO North America on Interviews – CEO North America, October – November 2022
  • CEO North America, August - September 2023 - CEO North America on CEO North America, December 2022 – January 2023
  • CEO North America, August - September 2023 - CEO North America on Why Tech Companies Are Moving to Texas and Florida
  • CEO North America, August - September 2023 - CEO North America on CEO North America, February 2023 – March 2023

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Editorials –
stuart.james@ceo-na.com

Advertising –
advertising@ceo-na.com

NEW YORK

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

 

MEXICO CITY

Paseo de la Reforma 296,
Floor 38
Mexico City
06600
MEXICO

HOUSTON

1201 Fannin St.
Suite 262
Houston, TX
77002
USA

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Editorials –
stuart.james@ceo-na.com

Advertising –
advertising@ceo-na.com

NEW YORK

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

HOUSTON

1201 Fannin St.
Suite 262
Houston, TX
77002
USA

MEXICO CITY

Paseo de la Reforma 296,
Floor 38
Mexico City
06600
MEXICO

CEO North America © 2022 - Sitemap

No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Warning: array_sum() expects parameter 1 to be array, null given in /home/ceonacom/public_html/wp-content/plugins/jnews-social-share/class.jnews-social-background-process.php on line 111